Q-omics provides the consensus-scored DPRX profile across patient tissues and cancer cell-line models. DPRX expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DPRX is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, DPRX RNA expression shows 8,829 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BRCA, and THYM as cancer lineages where DPRX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPRX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPRX survival associations across molecular data types. DPRX RNA expression shows survival associations in the most cancer types (15), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPRX RNA expression–survival associations across cancer types. High DPRX expression shows unfavorable associations in KIRC, CESC, MESO, ACC and LIHC, but favorable associations in KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for DPRX RNA expression.
This table summarizes DPRX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DPRX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPRX shows lower tumor expression in BRCA, LUAD, LUSC and THCA and higher tumor expression in KICH and KIRC. The BRCA box plot shows higher DPRX RNA expression in normal versus tumor tissue (log2 FC = −0.224, t-test p < 0.001).
This table shows molecular features associated with DPRX in patient tissues and cancer cell lines. In patient samples, DPRX shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DPRX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
